In the TCGA-LUAD dataset, we observed that MS4A6A expression was positively correlated with immune cell infiltration in the tumor microenvironment, especially macrophages, dendritic cells, and multiple immune checkpoints, suggesting that MS4A6A could be a potential biomarker for ICB therapy. Here, MS4A6A is linked to neoplasm.